DE69736597D1 - Gdnf rezeptor - Google Patents

Gdnf rezeptor

Info

Publication number
DE69736597D1
DE69736597D1 DE69736597T DE69736597T DE69736597D1 DE 69736597 D1 DE69736597 D1 DE 69736597D1 DE 69736597 T DE69736597 T DE 69736597T DE 69736597 T DE69736597 T DE 69736597T DE 69736597 D1 DE69736597 D1 DE 69736597D1
Authority
DE
Germany
Prior art keywords
gdnf
receptor
gdnfr
found
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736597T
Other languages
English (en)
Other versions
DE69736597T2 (de
Inventor
M Fox
Duanzhi Wen
Shuqian Jing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE69736597D1 publication Critical patent/DE69736597D1/de
Application granted granted Critical
Publication of DE69736597T2 publication Critical patent/DE69736597T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
DE69736597T 1996-04-22 1997-04-15 Gdnf rezeptor Expired - Lifetime DE69736597T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1590796P 1996-04-22 1996-04-22
US15907P 1996-04-22
US1722196P 1996-05-09 1996-05-09
US17221P 1996-05-09
US08/837,199 US6455277B1 (en) 1996-04-22 1997-04-14 Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US837199 1997-04-14
PCT/US1997/006281 WO1997040152A1 (en) 1996-04-22 1997-04-15 Glial cell line-derived neurotrophic factor receptor

Publications (2)

Publication Number Publication Date
DE69736597D1 true DE69736597D1 (de) 2006-10-12
DE69736597T2 DE69736597T2 (de) 2006-12-21

Family

ID=27360445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736597T Expired - Lifetime DE69736597T2 (de) 1996-04-22 1997-04-15 Gdnf rezeptor

Country Status (19)

Country Link
US (3) US6455277B1 (de)
EP (1) EP0909316B1 (de)
JP (1) JP2000509271A (de)
KR (1) KR20000010571A (de)
CN (1) CN1219967A (de)
AT (1) ATE338115T1 (de)
AU (1) AU720092B2 (de)
BR (1) BR9708959A (de)
CA (1) CA2250704C (de)
CZ (1) CZ324598A3 (de)
DE (1) DE69736597T2 (de)
EA (1) EA002924B1 (de)
ES (1) ES2271968T3 (de)
HU (1) HUP9902640A3 (de)
IL (1) IL126553A0 (de)
NO (1) NO984757L (de)
NZ (1) NZ332256A (de)
SK (1) SK140398A3 (de)
WO (1) WO1997040152A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) * 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
WO1997044356A2 (en) * 1996-05-08 1997-11-27 Biogen, Inc. RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH
US6677135B1 (en) * 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US20020068361A1 (en) * 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
AU7165998A (en) * 1997-05-30 1998-12-30 Amgen, Inc. Neurotrophic factor receptors
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
FI20000394A0 (fi) * 2000-02-21 2000-02-21 Airaksinen Matti GFRa4:n sukuisia tai siitä johdettuja aineita sekä niiden käyttö
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
AU2005258335B2 (en) 2004-06-24 2011-03-17 Biogen Ma Inc. Treatment of conditions involving demyelination
CA2583308C (en) * 2004-10-08 2020-01-07 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
SG163591A1 (en) 2005-07-08 2010-08-30 Biogen Idec Inc Sp35 antibodies and uses thereof
AU2006311828B2 (en) * 2005-11-04 2013-07-11 Biogen Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
AU2017357931A1 (en) 2016-11-10 2019-06-20 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
RU2690498C1 (ru) * 2018-05-17 2019-06-04 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Способ получения ноотропной композиции на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека
RU2732600C1 (ru) * 2019-12-26 2020-09-21 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях гипоксии, и способ ее получения
RU2752906C2 (ru) * 2019-12-26 2021-08-11 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях теплового шока, и способ ее получения

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
HU220795B1 (hu) 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
CA2250704A1 (en) 1997-10-30
JP2000509271A (ja) 2000-07-25
ES2271968T3 (es) 2007-04-16
US6455277B1 (en) 2002-09-24
HUP9902640A2 (hu) 1999-11-29
IL126553A0 (en) 1999-08-17
SK140398A3 (en) 1999-04-13
BR9708959A (pt) 1999-08-03
CZ324598A3 (cs) 1999-01-13
AU720092B2 (en) 2000-05-25
NO984757D0 (no) 1998-10-12
EP0909316A1 (de) 1999-04-21
NO984757L (no) 1998-12-21
US20030175876A1 (en) 2003-09-18
AU2730997A (en) 1997-11-12
CA2250704C (en) 2005-04-12
EA199800933A1 (ru) 1999-04-29
EP0909316B1 (de) 2006-08-30
HUP9902640A3 (en) 2001-11-28
DE69736597T2 (de) 2006-12-21
CN1219967A (zh) 1999-06-16
NZ332256A (en) 2000-03-27
EA002924B1 (ru) 2002-10-31
ATE338115T1 (de) 2006-09-15
WO1997040152A1 (en) 1997-10-30
KR20000010571A (ko) 2000-02-15
US20060166325A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
ATE338115T1 (de) Gdnf rezeptor
Bennett et al. Chemical cross-linking with thiol-cleavable reagents combined with differential mass spectrometric peptide mapping—a novel approach to assess intermolecular protein contacts
WO1997033995A3 (en) Extracellular matrix signalling molecules
Goulding et al. Role of H5 domain in determining pore diameter and ion permeation through cyclic nucleotide-gated channels
DK1179067T3 (da) Neurobeskyttende egenskaber hos GDF-15, et medlem af TGF-beta-superfamilien
ATE428785T1 (de) Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
WO1998054213A3 (en) Neurotrophic factor receptors
KR960706558A (ko) 골 발육 촉진성 단백질의 돌연변이체(mutants of bone morphogenetic proteins)
CA2471762A1 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
AU1207301A (en) Stabilized proteins
DE69732631D1 (de) Metabotropische gaba(b) rezeptoren, rezeptoren-spezifische liganden und deren anwendungen
Fernández et al. Membrane fractionation of a β-lactoglobulin tryptic digest: Effect of the pH
AU2154801A (en) Method for linking molecular substances
AU3143897A (en) Oligonucleotides which specifically bind retroviral nucleocapsid proteins
He et al. Identification of GABAB receptor in rat testis and sperm
WO2021211631A3 (en) Single molecule n-terminal sequencing using electrical signals
AU3472101A (en) Cyr61 compositions and methods
WO1997032020A3 (en) Shc proteins
WO1999030165A3 (en) Processes for identifying a solvent condition suitable for determining a biophysical property of a protein
Kondo et al. Coexpression of GABAA receptor γ1 and γ2 subunits in the rat trigeminal ganglion
WO1998054213B1 (en) Neurotrophic factor receptors
Kikkawa et al. Identification of laminin α5 short arm peptides active for endothelial cell attachment and tube formation
EP0361956A3 (de) Expression von rekombinanten Proteinen mit niedrigem Molekulargewicht
Mizuno et al. Localization of molecules involved in cytokine receptor signaling in the rat trigeminal ganglion
Maruyama et al. Characteristics of brain injury-derived neurotrophic peptide-binding sites on rat brain synaptosomes and neurons in culture

Legal Events

Date Code Title Description
8364 No opposition during term of opposition